JPWO2022145420A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022145420A5 JPWO2022145420A5 JP2022573085A JP2022573085A JPWO2022145420A5 JP WO2022145420 A5 JPWO2022145420 A5 JP WO2022145420A5 JP 2022573085 A JP2022573085 A JP 2022573085A JP 2022573085 A JP2022573085 A JP 2022573085A JP WO2022145420 A5 JPWO2022145420 A5 JP WO2022145420A5
- Authority
- JP
- Japan
- Prior art keywords
- cho cells
- polymer
- culture
- gel fiber
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 239000000835 fiber Substances 0.000 description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 9
- 229940072056 alginate Drugs 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012792 core layer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- FOPYSUNKHOANAQ-UHFFFAOYSA-N Cl.NCCNC(C1=CC=C(C=C1)CN=[N+]=[N-])=O Chemical compound Cl.NCCNC(C1=CC=C(C=C1)CN=[N+]=[N-])=O FOPYSUNKHOANAQ-UHFFFAOYSA-N 0.000 description 1
- OEFBTXPTHBIGGD-UHFFFAOYSA-N Cl.NCCOCCOCCNC(C1=CC=C(C=C1)N=[N+]=[N-])=O Chemical compound Cl.NCCOCCOCCNC(C1=CC=C(C=C1)N=[N+]=[N-])=O OEFBTXPTHBIGGD-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- GEQZRAYNKMRFKI-UHFFFAOYSA-N NCC1=CC=C(CNC(COC2C#CCCCCC2)=O)C=C1 Chemical compound NCC1=CC=C(CNC(COC2C#CCCCCC2)=O)C=C1 GEQZRAYNKMRFKI-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020219024 | 2020-12-28 | ||
| JP2021104094 | 2021-06-23 | ||
| PCT/JP2021/048567 WO2022145420A1 (ja) | 2020-12-28 | 2021-12-27 | 新規な多層ポリマーコーティング架橋アルギン酸ゲルファイバ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022145420A1 JPWO2022145420A1 (https=) | 2022-07-07 |
| JPWO2022145420A5 true JPWO2022145420A5 (https=) | 2025-01-06 |
Family
ID=82260786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573085A Pending JPWO2022145420A1 (https=) | 2020-12-28 | 2021-12-27 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240132854A1 (https=) |
| EP (1) | EP4268857A4 (https=) |
| JP (1) | JPWO2022145420A1 (https=) |
| KR (1) | KR20230127997A (https=) |
| AU (1) | AU2021414759A1 (https=) |
| CA (1) | CA3203302A1 (https=) |
| WO (1) | WO2022145420A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116710110A (zh) * | 2020-12-28 | 2023-09-05 | 持田制药株式会社 | 新型的多层聚合物涂层交联海藻酸凝胶纤维 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589591A (en) | 1986-07-03 | 1996-12-31 | Advanced Magnetics, Inc. | Endotoxin-free polysaccharides |
| JPH031931A (ja) | 1989-05-30 | 1991-01-08 | Toshiba Seiki Kk | 加熱シール装置 |
| WO1993013136A1 (en) | 1991-12-20 | 1993-07-08 | Howmedica Inc. | Ultra-pure polysaccharide materials for medical use |
| JPH08269102A (ja) | 1995-03-30 | 1996-10-15 | Shiseido Co Ltd | エンドトキシンフリーのβ１，３−グルカン及びその製造法並びに医療用ゲル素材 |
| JPH09324001A (ja) | 1996-04-02 | 1997-12-16 | Kyowa Hakko Kogyo Co Ltd | ヒアルロン酸ナトリウムの精製法 |
| JP2005036036A (ja) | 2003-07-16 | 2005-02-10 | Tanabe Seiyaku Co Ltd | エンドトキシン除去方法 |
| JP4986273B2 (ja) | 2005-09-15 | 2012-07-25 | 持田製薬株式会社 | アルギン酸を含む創傷被覆材 |
| EP2489779B1 (en) | 2009-10-14 | 2019-01-09 | The University of Tokyo | Coated micro gel fibers |
| US9090868B2 (en) * | 2010-07-12 | 2015-07-28 | President And Fellows Of Harvard College | Alginate hydrogel fibers and related materials |
| EP2680862B1 (en) * | 2011-03-04 | 2016-07-20 | Wake Forest University Health Sciences | Encapsulated cells for hormone replacement therapy |
| JP6074765B2 (ja) | 2013-01-18 | 2017-02-08 | 国立大学法人 東京大学 | 移植用神経束及びその製造方法 |
| CN103981147B (zh) * | 2013-02-08 | 2017-11-10 | 中国科学院上海生命科学研究院 | 一种新的制备肝实质细胞的方法 |
| JP6332782B2 (ja) | 2013-06-07 | 2018-05-30 | 国立大学法人 鹿児島大学 | 細胞凝集塊作製法 |
| WO2015178427A1 (ja) | 2014-05-20 | 2015-11-26 | 国立大学法人 東京大学 | 中空マイクロファイバ |
| JP6439918B2 (ja) | 2014-10-17 | 2018-12-19 | 国立大学法人 東京大学 | ３次元細胞構造体の製造方法 |
| US11655343B2 (en) * | 2016-03-24 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Alginate hydrogel compositions |
| SG11201811763SA (en) * | 2016-07-18 | 2019-02-27 | Eth Zuerich | B-cell-mimetic cells |
| JP7090868B2 (ja) | 2017-10-19 | 2022-06-27 | 国立大学法人 東京大学 | 接着剤及びその使用 |
| JP7034467B2 (ja) | 2017-10-20 | 2022-03-14 | 国立大学法人 東京大学 | 細胞の三次元培養方法、細胞構造体、細胞構造体の製造方法、細胞の運搬方法及び細胞の保存方法 |
| US20200392439A1 (en) | 2017-12-23 | 2020-12-17 | The University Of Tokyo | Array and use thereof |
| WO2019240219A1 (ja) * | 2018-06-14 | 2019-12-19 | 持田製薬株式会社 | 新規な架橋アルギン酸 |
| JP7388722B2 (ja) | 2018-08-10 | 2023-11-29 | 国立大学法人 東京大学 | アルギン酸中空マイクロファイバ |
| JP2023015413A (ja) | 2019-12-18 | 2023-02-01 | 持田製薬株式会社 | 化学架橋アルギン酸ゲルファイバ |
| CN114929754A (zh) | 2019-12-18 | 2022-08-19 | 持田制药株式会社 | 新型交联海藻酸 |
-
2021
- 2021-12-27 US US18/269,705 patent/US20240132854A1/en active Pending
- 2021-12-27 EP EP21915279.0A patent/EP4268857A4/en not_active Withdrawn
- 2021-12-27 AU AU2021414759A patent/AU2021414759A1/en not_active Abandoned
- 2021-12-27 WO PCT/JP2021/048567 patent/WO2022145420A1/ja not_active Ceased
- 2021-12-27 CA CA3203302A patent/CA3203302A1/en active Pending
- 2021-12-27 JP JP2022573085A patent/JPWO2022145420A1/ja active Pending
- 2021-12-27 KR KR1020237021149A patent/KR20230127997A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL1016435C1 (nl) | Kristallijne base van Citalopram. | |
| CN1335771A (zh) | 作为趋化因子受体活性调节剂的n－脲基烷基－哌啶化合物 | |
| WO2003037881A1 (en) | α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | |
| CN1092657C (zh) | 一釜法合成2－噁唑烷酮衍生物 | |
| CN1738605A (zh) | 改变药物晶体形成的方法 | |
| CA2706883A1 (en) | Methods of treating copd | |
| JPWO2022145420A5 (https=) | ||
| CN1042712A (zh) | β-内酰胺抗菌素水合物的制备方法 | |
| WO1988005656A1 (en) | Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide | |
| CN100439345C (zh) | 作为用于治疗 2型糠尿病和动脉硬化症的ppar调节剂的 3 - ( 2 -苯基 -噁唑-4-基甲氧基)环己基甲氧基乙酸衍生物和相关化合物 | |
| CN102101836A (zh) | S-奥拉西坦新晶型及其制备方法 | |
| JP2010520176A (ja) | ５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤 | |
| JPS603387B2 (ja) | 新規光学活性イミダゾリジン−２−オン誘導体およびその製法 | |
| JP2024525254A5 (https=) | ||
| CN1192121A (zh) | 钙通道的调整 | |
| FR2534915A1 (fr) | Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation | |
| CA2438828A1 (fr) | Derives d'arylcarbamates, preparation et utilisations | |
| CN1056688A (zh) | N-乙酯基-3-吗啉代-斯德酮亚胺或其盐与环糊精衍生物生成的包合配合物 | |
| CN1131153A (zh) | 1-氧代-2-(苯磺酰氨基)戊基哌啶衍生物，其制备方法及其药用 | |
| CN1281447A (zh) | (e)－3－[1－正丁基－5－[2－(2－羧基苯基)甲氧基－4－氯苯基]－1h－吡唑－4－基]－2－[(5－甲氧基－2,3－二氢苯并呋喃－6－基)甲基]丙－2－烯酸－精氨酸盐 | |
| CN1034929A (zh) | 结晶β-内酰胺溶剂化物的制备方法 | |
| TW455586B (en) | Process and intermediates for preparing 5-lipoxygenase inhibitors | |
| CN1022567C (zh) | 2-(1-戊基-3-胍基)-4-(2-甲基-4-咪唑基)噻唑的制备方法 | |
| CN1293055C (zh) | 哌啶衍生物晶体、其制备所用的中间体以及其制备方法 | |
| CN116396279B (zh) | 一种γ-丁烯酸内酯类衍生物及其制备方法与应用 |